CRISPR Therapeutics–Piper Jaffray: investor conference, 201811 supply service CRISPR Therapeutics at Piper Jaffray Healthcare Conference 2018

	Period	2018-11-28
	Region	New York, NY
	Country	United States (USA)
	Predecessor	CRISPR Therapeutics–Piper Jaffray: investor conference, 201711 supply service CRISPR Therapeutics at Piper Jaffray Healthcare Conference 2017
	Partner, 1st	CRISPR Therapeutics AG (Nasdaq: CRSP)
	Group	CRISPR Therapeutics (Group)
	Partner, 2nd	Piper Jaffray & Co. (NYSE: PJC)
	Today	Piper Sandler Companies (NYSE: PIPR)
	Group	Piper Sandler (Group)
	Product	Piper Jaffray Annual Healthcare Conference 2018 New York
	Product 2	CRISPR gene editing technology
	Person	Kulkarni, Samarth (Sam) (CRISPR Therapeutics 201712– promoted CEO before CBO)
	Person 2	Kim, Susan (CRISPR Therapeutics 201809 Investor Relations)

CRISPR Therapeutics AG. (11/21/18). "Press Release: CRISPR Therapeutics to Participate in Upcoming Investor Conferences". Zug & Cambridge, MA.

CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics, is scheduled to participate in the following investor conferences in November:

30th Annual Piper Jaffray Healthcare Conference
Date: Wednesday, November 28, 2018
Fireside Chat: 10:30 AM ET
Location: New York, NY

Barclays Gene Editing & Gene Therapy Summit
Date: Thursday, November 29, 2018
Presentation: 4:00 PM ET
Panel Discussion: 4:30 PM ETFocus on Gene Editing
Location: New York, NY

A live webcast of the Piper Jaffray fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.

About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer AG, Vertex Pharmaceuticals and ViaCyte, Inc.CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in London, United Kingdom. For more information, please visit www.crisprtx.com.

CRISPR Investor Contact:

Susan Kim
susan.kim@crisprtx.com

CRISPR Media Contact:

Jennifer Paganelli
WCG on behalf of CRISPR
347-658-8290
jpaganelli@wcgworld.com